Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report

BACKGROUND: Stereotactic body radiation therapy (SBRT) applied by helical tomotherapy (HT) is feasible for lung cancer in clinical. Using SBRT concurrently with erlotinib for non-small cell lung cancer (NSCLC) is not reported previously. CASE PRESENTATION: A 77-year-old man with stage III NSCLC, rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Chen-Hsi, Chang, Hou-Tai, Lin, Shih-Chiang, Chen, Yu-Jen, Wang, Li-Ying, Hsieh, Yen-Ping, Chen, Chien-An, Chong, Ngot-Swan, Lin, Shoei Long, Chen, Chun-Yi, Shueng, Pei-Wei
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022890/
https://www.ncbi.nlm.nih.gov/pubmed/21194444
http://dx.doi.org/10.1186/1471-2407-10-696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022890/
https://www.ncbi.nlm.nih.gov/pubmed/21194444
http://dx.doi.org/10.1186/1471-2407-10-696

Ejemplares similares